Amgen on the Hunt for $10B Acquisition

Source: Financial Times

Nov 10, 2015

U.S. biotech giant Amgen is looking to acquire a biotech company worth about $10 billion, according to Financial Times sources.

FT sources said Amgen is targeting biotech firms that have late-stage drugs which are almost commercial-ready.

Amgen's last major acquisition was in 2013, when it purchased Onyx Pharmaceuticals and its cancer drug Kyprolis for about $10 billion.

Sources did not reveal any potential acquisition targets.

Read the FT article (registration required)
Read the LA Business Journal release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments